Albany, New York (09/22/2014) – AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that it will present the clinical data on Tivozanib and Ficlatuzumab at the ESMO 2014 Congress. Ficlatuzumab is the HGF inhibitory antibody, and Tivozanib is the VEGF inhibitory antibody. The conference is scheduled from September 26 -September 30, 2014 in Madrid, Spain. President and the CEO, Tuan Ha-Ngoc, said that there is significant therapeutic value in AVEO’s clinical-stage product candidates.

George S. Mack of The Life Sciences Report interviewed Vernon Bernardino, a senior analyst in MLV & Co. and got to know the analyst’s view on the company Dynavax Technologies Corporation (NASDAQ:DVAX). Bernardino said that his company had a “buy” rating on DVAX stock with a price target of $5.00. Dynavax main strength is its hepatitis B vaccine known as Heplisav, which has undergone successful clinical studies. The results of the vaccine have been effective, and now the FDA has issued Dynavax a response letter to start up with its confirmatory Phase 3 study. However, Dynavax will need huge amount of funds to conduct Phase 3 clinical trials.

Trade Street Residential Inc (NASDAQ:TSRE) announced a quarterly dividend distribution for the third quarter 2014. It will pay a dividend of $0.095 per share. The self-managed REIT Company carries out its business operation in mid-sized cities as well as the suburban markets in larger cities. The regions covered are Texas and southeastern United States. Now, it will reward the shareholders with a dividend of $0.095 per share which will be payable on October 15, 2014 for a record date of September 30, 2014.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) said that it will present 15 abstracts from the CF research and development program at North American Cystic Fibrosis Conference scheduled from October 9 to October 11, 2014. Data from Phase 3 TRANSPORT and Traffic studies of lumacaftor used in combination with ivacaftor will be presented in the conference. It will also present the results of Phase 3 rollover study.